Gut microbiota and metabolome distinctive features in Parkinson disease: Focus on levodopa and levodopa-carbidopa intrajejunal gel.
LCIG
Parkinson
duodopa
levodopa
microbiota
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
15
09
2020
revised:
04
11
2020
accepted:
05
11
2020
pubmed:
14
11
2020
medline:
13
8
2021
entrez:
13
11
2020
Statut:
ppublish
Résumé
Recent data suggest that imbalances in the composition of the gut microbiota (GM) could exacerbate the progression of Parkinson disease (PD). The effects of levodopa (LD) have been poorly assessed, and those of LD-carbidopa intestinal gel (LCIG) have not been evaluated so far. The aim of this study was to identify the effect of LD and LCIG, in particular, on the GM and metabolome. Fecal DNA samples from 107 patients with a clinical diagnosis of PD were analyzed by next-generation sequencing of the V3 and V4 regions of the 16S rRNA gene. PD patients were classified in different groups: patients on LCIG (LCIG group, n = 38) and on LD (LD group, n = 46). We also included a group of patients (n = 23) without antiparkinsonian medicaments (Naïve group). Fecal metabolic extracts were evaluated by gas chromatography mass spectrometry. The multivariate analysis showed a significantly higher abundance in the LCIG group of Enterobacteriaceae, Escherichia, and Serratia compared to the LD group. Compared to the Naïve group, the univariate analysis showed a reduction of Blautia and Lachnospirae in the LD group. Moreover, an increase of Proteobacteria, Enterobacteriaceae, and a reduction of Firmicutes, Lachnospiraceae, and Blautia was found in the LCIG group. No significant difference was found in the multivariate analysis of these comparisons. The LD group and LCIG group were associated with a metabolic profile linked to gut inflammation. Our results suggest that LD, and mostly LCIG, might significantly influence the microbiota composition and host/bacteria metabolism, acting as stressors in precipitating a specific inflammatory intestinal microenvironment, potentially related to the PD state and progression.
Sections du résumé
BACKGROUND AND PURPOSE
Recent data suggest that imbalances in the composition of the gut microbiota (GM) could exacerbate the progression of Parkinson disease (PD). The effects of levodopa (LD) have been poorly assessed, and those of LD-carbidopa intestinal gel (LCIG) have not been evaluated so far. The aim of this study was to identify the effect of LD and LCIG, in particular, on the GM and metabolome.
METHODS
Fecal DNA samples from 107 patients with a clinical diagnosis of PD were analyzed by next-generation sequencing of the V3 and V4 regions of the 16S rRNA gene. PD patients were classified in different groups: patients on LCIG (LCIG group, n = 38) and on LD (LD group, n = 46). We also included a group of patients (n = 23) without antiparkinsonian medicaments (Naïve group). Fecal metabolic extracts were evaluated by gas chromatography mass spectrometry.
RESULTS
The multivariate analysis showed a significantly higher abundance in the LCIG group of Enterobacteriaceae, Escherichia, and Serratia compared to the LD group. Compared to the Naïve group, the univariate analysis showed a reduction of Blautia and Lachnospirae in the LD group. Moreover, an increase of Proteobacteria, Enterobacteriaceae, and a reduction of Firmicutes, Lachnospiraceae, and Blautia was found in the LCIG group. No significant difference was found in the multivariate analysis of these comparisons. The LD group and LCIG group were associated with a metabolic profile linked to gut inflammation.
CONCLUSIONS
Our results suggest that LD, and mostly LCIG, might significantly influence the microbiota composition and host/bacteria metabolism, acting as stressors in precipitating a specific inflammatory intestinal microenvironment, potentially related to the PD state and progression.
Substances chimiques
Antiparkinson Agents
0
Drug Combinations
0
Gels
0
RNA, Ribosomal, 16S
0
Levodopa
46627O600J
Carbidopa
MNX7R8C5VO
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1198-1209Informations de copyright
© 2020 European Academy of Neurology.
Références
Cersosimo MG, Benarroch EE. Pathological correlates of gastrointestinal dysfunction in Parkinson’s disease. Neurobiol Dis. 2012;46:559-564.
Zhao Y, Yu Y-B. Intestinal microbiota and chronic constipation. SpringerPlus. 2016;5:1130.
Pietrucci D, Cerroni R, Unida V, et al. Dysbiosis of GM in a selected population of Parkinson's patients. Parkinsonism Relat Disord. 2019; 65:124-130.
Keshavarzian A, Green SJ, Engen PA, et al. Colonic bacterial composition in Parkinson’s disease. Mov Disord. 2015;30:1351-1360.
Unger MM, Spiegel J, Dillmann KU, et al. Short chain fatty acids and gut microbiota differ between patients with Parkinson’s disease and age-matched controls. Parkinsonism Relat Disord. 2016;32:66-72.
Scheperjans F, Aho V, Pereira PA, et al. Gut microbiota are related to Parkinson’s disease and clinical phenotype. Mov Disord. 2015;30:350-358.
Hopfner F, Künstner A, Müller SH, et al. Gut microbiota in Parkinson disease in a northern German cohort. Brain Res. 2017;1667:41-45.
Barichella M, Severgnini M, Cilia R, et al. Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism. Mov Disord. 2019;34(3):396-405.
Li W, Wu X, Hu X, et al. Structural changes of gut microbiota in parkinson’s disease and its correlation with clinical features. Sci China Life Sci. 2017;60:1223-1233.
Bedarf JR, Hildebrand F, Coelho LP, et al. Functional implications of microbial and viral gut metagenome chagesinearly stage l-dopa-naïve parkinson’s disease patients. Genome Med. 2017;9:39.
Hill-Burns EM, Debelius JW, Morton J, et al. Parkinson’s disease and Parkinson’s disease medications have distinct signatures of the gut microbiome. Mov Disord. 2017;32:739-749.
Hasegawa S, Goto S, Tsuji H, et al. Intestinal dysbiosis and lowered serum lipopolysaccharide-binding protein in parkinson’s disease. PLoS One. 2015;10:e0142164.
Salat D, Tolosa E. Levodopa in the treatment of Parkinson’s disease: current status and new developments. J. Parkinsons Dis. 2013;3:255-269.
Van Kessel SP, Frye AK, El-Gendy AO, et al. Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson’s disease. Nat. Commun. 2019;10:310.
Goldin BR, Peppercorn MA, Goldman P. Contributions of host and intestinal microflora in the metabolism of L-dopa by the rat. J Pharmacol Exp Ther. 1973;186:160-166.
Maini Rekdal V, Bess EN, Bisanz JE, Turnbaugh PJ, Balskus EP. Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism. Science. 2019;364 6445:
Sofi F, Dinu M, Pagliai G, Marcucci R, Casini A. Validation of a literature-based adherence score to Mediterranean diet:the MEDI-LITE score. Int J Food Sci Nutr. 2017;68(6):757-762. https://doi.org/10.1080/09637486.2017.1287884
Dhariwal A, Chong J, Habib S, King IL, Agellon LB, Xia J. Microbiome Analyst: a web-based tool for comprehensive statistical, visual and meta-analysis of microbiome data. Nucleic Acids Res. 2017;45:180-188.
IBM Corp. IBM SPSS Statistics for Windows, Version 25.0. Armonk, NY: IBM Corp (Released 2017).
Berthold MR, Cebron N, Dill F. KNIME - The Konstanz Information Miner. ACM SIGKDD Explorations. 2009;11 1:1-6.
Nishiwaki H, Ito M, Ishida T, et al. Meta-analysis of gut dysbiosis in Parkinson’s disease. Mov Disord. 2020. 10.1002/mds.28119. 35 9:1626-1635.
Weis S, Schwiertz A, Unger M, et al. Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota. NPJ Parkinsons Dis. 2019;5:28. https://doi.org/10.1038/s41531-019-0100-x
Zeng MY, Inohora N, Nunez G, et al. Mechanisms of inflammation-driven bacterial dysbiosis in the gut. Mucosal Immunol. 2016;10:18-26. https://doi.org/10.1038/mi.2016.75.
Bergman EN. Energy contributions of volatile fatty acids from the gastrointestinal tract in various species. Physiol Rev. 1990;70:567-590.
Huuskonen J, Suuronen T, Nuutinen T, Kyrylenko S, Salminen A. Regulation of microglial inflammatory response by sodium butyrate and short-chain fatty acids. Br J Pharmacol. 2004;141:874-880.
Tremlett H, Bauer KC, Appel-Cresswell S, Finlay BB, Waubant E. The gut microbiome in human neurological disease: a review. Ann Neurol. 2018;81:369-382.
Mulak A. A controversy on the role of short-chain fatty acids in the pathogenesis of Parkinson's disease. Mov Disord. 2018;33(3):398-401. https://doi.org/10.1002/mds.27304
Sun MF, Shen YQ. Dysbiosis of gut microbiota and microbial metabolites in Parkinson’s disease. Ageing Res Rev. 2018;45:53-61.
Figura M, Kuśmierska K, Bucior E, et al. Serum amino acid profile in patients with Parkinson's disease. PLoS One. 2018;13:e0191670.
Lei S, Kamada N, Chen GY, Inohara N, Nunez G. Control of pathogens and pathobionts by the gut microbiota. Nat Immunol. 2013;14:685-690.
Nutt JG, Woodward WR, Hammerstad JP, Carter JH, Anderson JL. The on-off phenomenon in Parkinson’s disease: relation to levodopa absorption and transport. N Engl J Med. 1984;310(8):483-488.
Peppercorn MA, Goldman P. Caffeic acid metabolism by bacteria of the human gastrointestinal tract. J Bacteriol. 1971;108(3):996-1000.
Barichella M, Savergnini M, Cilia R, et al. Unraveling gut microbiota in Parkinson’s disease and atypical Parkinsonism. Mov Disord. 2019;34(3):396-405. https://doi.org/10.1002/mds.27581.
Zhao Y, Yu YB. Intestinal microbiota and chronic constipation. Springerplus. 2016;5:1130. https://doi.org/10.1186/s40064-016-2821-1
Hannoun A, Ward D, Flahive J, et al. Effect of Levodopa on gut microbiome in Parkinson’s Disease (PD) (abstract). Mov. Disord. 2019;34(suppl 2).887
Vascellari S, Palmas V, Melis M, et al. Gut microbiota and metabolome alterations associated with Parkinson’s disease. mSystems. 2020;5(5): e00561-e00620. https://doi.org/10.1128/mSystems.00561-20
Accepted Manuscript Number: IJBIOMAC-D-20-05004R1.